News Releases

Month Year

Email Alerts

May 22, 2023

Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference
May 8, 2023

Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"
May 5, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 4, 2023

Insmed Reports First Quarter 2023 Financial Results and Provides Business Update
Apr 24, 2023

Insmed to Host Investor and Analyst Event on May 8, 2023
Apr 20, 2023

Insmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023
Apr 6, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 31, 2023

Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis
Mar 24, 2023

Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference
Mar 3, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 1, 2023

Insmed To Present at Two March Conferences
Feb 23, 2023

Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Feb 9, 2023

Insmed to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, February 23, 2023
Feb 7, 2023

Insmed To Present at the SVB Securities Global Biopharma Conference
Feb 3, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 20, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 6, 2023

Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference
Jan 3, 2023

Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 6, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 30, 2022

Insmed To Present at the Nasdaq 47th Investor Conference
Nov 4, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 1, 2022

Insmed To Present at Three November Conferences
Oct 27, 2022

Insmed Ranks No. 1 on Science's 2022 Top Biopharma Employers List
Oct 27, 2022

Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 19, 2022

Insmed Announces Strategic Financings Totaling $775 Million
Oct 13, 2022

Insmed to Host Third Quarter 2022 Financial Results Conference Call on Thursday, October 27, 2022
Oct 7, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 6, 2022

Insmed Holds Inaugural Global Day of Good - A Company-Wide Day of Service
Sep 7, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 6, 2022

Insmed To Present at Two September Conferences
Aug 5, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 4, 2022

Insmed Reports Second Quarter 2022 Financial Results and Provides Business Update
Jul 21, 2022

Insmed to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022
Jul 8, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 3, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 23, 2022

Insmed Names Drayton Wise Chief Commercial Officer
May 17, 2022

Insmed Presents New Data Across Three Pillars at American Thoracic Society 2022 International Conference
May 17, 2022

Insmed To Present at the H.C. Wainwright Annual Global Life Sciences Conference
May 6, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 5, 2022

Insmed Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 21, 2022

Insmed to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
Apr 7, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 28, 2022

Insmed to Showcase New Data Across Three Pillars at the American Thoracic Society 2022 International Conference
Mar 4, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 3, 2022

Insmed To Present at the Cowen 42nd Annual Health Care Conference
Feb 17, 2022

Insmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update

--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $56.1 Million for the Fourth Quarter and $188.5 Million for the Full Year 2021; Anticipate at Least 30% Year Over Year Annual Growth for 2022--
Feb 10, 2022

Insmed To Present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference
Feb 4, 2022

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 27, 2022

Insmed to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide a Business and Pipeline Update on Thursday, February 17, 2022
Jan 4, 2022

Insmed To Present at the 40th Annual J.P. Morgan Healthcare Conference

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

View the latest Insmed Investor Presentation

Download

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa

Our Global Company

Current Clinical Trials

Our Research Team

Our Global Company

Current Clinical Trials

Our Research Team

Footer